American Society of Clinical Oncology

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

American Society of Clinical Oncology
Formation1964 (1964)
HeadquartersAlexandria, Virginia
Membership
Nearly 45,000
Official language
English
President
Lori J. Pierce[1]
Websiteasco.org

Physician education

edit

ASCO offers educational resources for cancer physicians and other health care professionals of clinical oncology. These include scientific meetings, educational conferences, professional workshops, and special symposia on issues of particular relevance and importance to oncologists and researchers. It also produced the patient information website, Cancer.Net.

It publishes numerous journals, books, newsletters, and online and multimedia resources; it publishes the Journal of Clinical Oncology (JCO),[2] the JCO Oncology Practice (JCO OP),[3] and the JCO Global Oncology (JCO GO),[4] JCO Clinical Cancer Informatics, which publishes clinically relevant research based on biomedical informatics methods and processes applied to cancer-related data, information, and images,[5] and JCO Precision Oncology, which publishes original research, reports, opinions, and reviews related to precision oncology and genomics-driven care of patients with cancer.[6]

ASCO also publishes special curricula to address the specific educational needs of cancer professionals.

Publications

edit

Initiatives

edit

Created by members of ASCO, the Conquer Cancer Foundation of ASCO is a 501(c)(3) charitable organization. Since the inception of its grants and awards program in 1984, Conquer Cancer has awarded more than $90 million in funding through nearly 1,500 grants and awards to researchers in 65 countries. In 2015, the foundation launched The Campaign to Conquer Cancer, a comprehensive campaign to raise $150 million to fund cancer research, support Conquer Cancer's top priorities, and bring national awareness to the Foundation.

The ASCO post also reviews books and journals written by notable authors in medicine and other domains. ASCO reviewed the Second Edition of Advanced Healthcare Through Personalized Medicine[7] in 2022 authored by Priya Hays, which was described as the “depth of technical information and wellspring of novel advances carefully woven into a personalized medicine matrix are admirable” and “a top-notch operation from cover to cover”.[8]

ASCO's patient information website, Cancer.NET, is supported by the Conquer Cancer Foundation of ASCO. Cancer LINQ is ASCO's data platform initiative. It was created to give oncologists a robust quality monitoring system that collects and analyzes data from all patient encounters to improve quality of care. ASCO published its Value Framework in 2015 [9] and updated it in 2016.[10] This provides physicians and patients with a tool to assess and compare the value of different drugs in an era of skyrocking anticancer drug costs.[11]

See also

edit

References

edit
  1. ^ "Lori Pierce, MD elected president of ASCO". medicine.umich.edu. January 9, 2019. Retrieved February 15, 2021.
  2. ^ "About JCO". Journal of Clinical Oncology. Retrieved 16 December 2015.
  3. ^ "About JOP". Journal of Oncology Practice. Retrieved 16 December 2015.
  4. ^ "General Information". Journal of Global Oncology. Archived from the original on 2020-01-08. Retrieved 2019-06-17.
  5. ^ "JCO Clinical Cancer Informatics". American Society of Clinical Oncology.
  6. ^ "JCO Precision Oncology". American Society of Clinical Oncology.
  7. ^ Hays, Priya (July 2019). "Personalized medicine: paradigm shift or revolution". Genetics in Medicine. 21 (7): 1662. doi:10.1038/s41436-018-0379-8. ISSN 1530-0366. PMID 30467405.
  8. ^ Piana, Ronald (May 25, 2022). "A Second Edition Adds New Value to Personalized Medicine". ascopost.com. Retrieved 2023-11-22.
  9. ^ Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. (August 2015). "American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options". Journal of Clinical Oncology. 33 (23): 2563–77. doi:10.1200/JCO.2015.61.6706. PMC 5015427. PMID 26101248.
  10. ^ Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, et al. (August 2016). "Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received". Journal of Clinical Oncology. 34 (24): 2925–34. doi:10.1200/JCO.2016.68.2518. PMID 27247218.
  11. ^ Røe OD (September 2017). "The High Cost of New Cancer Therapies-A Challenge of Inequality for All Countries". JAMA Oncology. 3 (9): 1169–1170. doi:10.1001/jamaoncol.2016.6335. PMID 28033441.
edit